We develop intestine-targeted LNPs that withstand gastrointestinal conditions, reach defined intestinal segments and cell populations, and deliver functional payloads — supported end to end from lipid design and ligand engineering to enteric formulation, characterization, and in vivo intestinal evaluation.
Intestine-targeted LNPs are engineered to deliver nucleic acids, proteins, and small molecules to the gastrointestinal tract, where conventional LNPs fail on two fronts: systemically administered particles accumulate almost entirely in the liver, and orally administered particles are degraded by gastric acid, bile salts, and luminal enzymes before reaching the epithelium. Intestinal formulations therefore combine gastrointestinal-stability engineering, mucus-compatible surface design, and transporter- or receptor-directed targeting to achieve delivery to enterocytes, M cells, immune cells, or inflammatory-cell populations in specific intestinal segments.
BOC Sciences provides integrated targeted LNP development for intestinal applications, covering ionizable lipid screening, intestinal-cell-targeting ligand synthesis, surface functionalization, payload encapsulation, enteric and microencapsulated format development, and cellular and in vivo evaluation. We support customized LNPs for mRNA, siRNA, ASO, plasmid DNA, genome-editing payloads, and small molecules, with formulation strategies selected according to the target intestinal segment, target cell type, and administration route.
Intestine-Targeted Lipid Nanoparticle IllustrationOur development services integrate lipid chemistry, gastrointestinal-stability engineering, surface targeting, and biological evaluation to address the barriers that limit intestinal delivery. Projects can start with an existing LNP formulation, a candidate targeting ligand, or only a delivery objective defined by intestinal segment and target cell. We customize the development scope according to payload properties, administration route, and the biological readouts that matter most for your program.
We investigate how ionizable lipid structures and supporting lipid components influence gastrointestinal stability, epithelial interaction, and intestinal-versus-hepatic distribution.
We develop ligand-functionalized LNPs to improve interactions with defined intestinal cell populations, including enterocytes, M cells, goblet-cell-associated models, and intestinal macrophages.
We integrate lipid composition, targeting modifications, and payload properties into formulation formats that survive administration and release the payload at the intended intestinal site.
We evaluate candidate LNPs across particle, barrier, and tissue levels to confirm that gastrointestinal stability and epithelial uptake translate into functional payload delivery in the intestine.
Intestine-targeted LNPs can be developed through lipid-composition engineering, gastrointestinal-stability optimization, gastroprotective dosage formats, and surface ligand functionalization. BOC Sciences supports lipid design and synthesis, ligand modification, LNP formulation, and delivery evaluation. The following strategies can be applied individually or combined into a multi-layer design.
Intestinal accumulation can be pursued by selecting ionizable lipid structures and lipid compositions that favor epithelial interaction and intestinal tissue retention over hepatic uptake. BOC Sciences supports customized ionizable lipid design, synthesis, structural screening, and LNP formulation.
Research reference: Reversely engineered LNPs composed of phosphatidic acid, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol (5:2:3) for oral IL-22 mRNA delivery to injured colonic mucosa (~200 nm, −18 mV) (Biomaterials, 2022); novel ionizable-lipid LNPs (L15) that reduced the efficacious dose of anti-TNF-α locked nucleic acid 30-fold in a colitis model (Nature Communications, 2025).
Orally administered LNPs must remain intact through gastric acid, bile salts, lipases, and luminal nucleases. BOC Sciences supports composition and process optimization to keep particles and payloads stable until they reach the target segment.
Research reference: Arginine-modified lipid nanoparticles carrying TNF-α siRNA remained structurally intact for 12 hours in simulated digestive fluids with approximately 84.5% payload protection, enabling oral silencing in colitis mice (Chemical Engineering Journal, 2025).
Segment-selective delivery, particularly to the colon, can be achieved by enclosing stable LNPs inside gastroprotective carriers that release only under intestinal conditions. BOC Sciences supports coating and microencapsulation development, release testing, and integrated LNP-microparticle formulation.
Research reference: TNF-α siRNA-loaded LNPs microencapsulated in gastroresistant alginate particles (≥90% encapsulation of both siRNA and LNPs) targeted the inflamed colon and markedly reduced tissue damage in a TNBS-induced colitis model (Drug Delivery and Translational Research, 2025).
Cell-level specificity can be added by displaying transporter substrates, antibodies, single-domain antibodies, or peptides on the LNP surface. BOC Sciences supports ligand selection, synthesis, conjugation chemistry, and functionalized LNP development.
Research reference: Cholic acid–PEG-lipid modification increased bile-acid-transporter-mediated uptake and protein expression of mRNA-LNPs in differentiated intestinal epithelial cell models (Journal of Nanoparticle Research, 2024); APN-targeted VHH single-domain antibody-functionalized LNPs achieved epithelial uptake and transcytosis across the gut barrier in intestinal organoids and in vivo (Journal of Controlled Release, 2025).
Share your payload, target segment, and administration route. BOC Sciences can help evaluate feasible design options, synthesize relevant components, and develop a comparative formulation strategy.
BOC Sciences develops intestine-targeted LNPs for the payload classes most frequently used in gastrointestinal delivery research. Each payload requires a matched loading strategy, gastrointestinal-stability approach, and functional readout, and we help connect intestinal-targeting design with payload-specific formulation requirements.
| Payload Type | Supported Uses & Intestine-Targeted LNP Development Considerations | Request Information |
|---|---|---|
| Intestine-Targeted LNP for mRNA | Designed for epithelial and immune-cell expression studies in the gastrointestinal tract, including cytokine and barrier-factor expression. Development focuses on mRNA integrity under luminal conditions, epithelial uptake, and intestinal-versus-hepatic expression ratios, supported by our lipid nanoparticles for mRNA delivery platform. | Inquiry |
| Intestine-Targeted LNP for siRNA | Suitable for local gene silencing in epithelial and inflammatory-cell populations, including TNF-α and other cytokine-pathway targets. Development evaluates siRNA retention through simulated gastrointestinal exposure, epithelial and macrophage uptake, and inflamed-tissue enrichment. | Inquiry |
| Intestine-Targeted LNP for miRNA | Applicable to miRNA replacement and inhibition studies in intestinal epithelium and immune-cell models. Development addresses duplex loading, nuclease protection during luminal transit, and target modulation in intestinal cell panels, drawing on our lipid nanoparticles for miRNA delivery experience. | Inquiry |
| Intestine-Targeted LNP for Antisense Oligonucleotides | Designed for splice-modifying and knockdown oligonucleotide research in intestinal models, where high-dose requirements make delivery efficiency decisive. Development focuses on oligonucleotide loading, epithelial uptake, and dose-sparing behavior, supported by our lipid nanoparticles for ASO delivery services. | Inquiry |
| Intestine-Targeted LNP for circRNA and saRNA | Designed for payloads requiring strong protection and sustained expression in the gastrointestinal tract. Development considers payload integrity during luminal exposure, encapsulation behavior, and expression duration in intestinal cell models, supported by our lipid nanoparticles for circRNA delivery platform. | Inquiry |
| Intestine-Targeted LNP for pDNA | Applicable to plasmid-based expression research in intestinal epithelial models, where nuclear delivery after epithelial uptake is the limiting step. Development addresses large-payload condensation, particle size control, and epithelial transport, building on our lipid nanoparticles for pDNA delivery capabilities. | Inquiry |
| Intestine-Targeted LNP for Cas9 mRNA and sgRNA | Designed for local genome-editing research in intestinal epithelium, where transient Cas9 expression limits prolonged nuclease exposure. We evaluate co-loading of Cas9 mRNA and guide RNA, editing readouts in intestinal cell and organoid models, and particle consistency after gastrointestinal-format processing, drawing on our lipid nanoparticles for CRISPR RNP delivery capabilities. | Inquiry |
| Intestine-Targeted LNP for Protein and Peptide | Applicable to enzymes, signaling proteins, and peptide payloads intended for intestinal delivery research, including barrier-protective factors. Formulation work emphasizes protection from proteolysis, mucosal uptake, and preserved biological activity, drawing on our protein encapsulation in LNPs experience. | Inquiry |
| Intestine-Targeted LNP for Small Molecule | Designed for hydrophobic, amphiphilic, or ionizable small molecules studied in intestinal inflammation, permeability, and metabolism research. We evaluate drug–lipid compatibility, loading method, retention during gastrointestinal transit, and release behavior at the target segment, supported by our lipid nanoparticles for small molecule delivery services. | Inquiry |
| Intestine-Targeted LNP for Antigen | Suitable for mucosal immune-priming studies in Peyer's patch and intestinal immune-cell models. Development addresses antigen loading, epithelial and M-cell uptake, and immune-cell delivery after oral administration, supported by our lipid nanoparticles for antigen delivery platform. | Inquiry |
| Intestine-Targeted LNP for Fluorescent and Tracking Labels | Supports labeled particles used to map intestinal segment distribution, mucus and epithelial localization, and inflamed-versus-healthy tissue enrichment, enabled by our tracking-labeled lipid nanoparticles capabilities. | Inquiry |
| Intestine-Targeted LNP for Custom Payload | Developed for unusual payloads, co-delivery systems, or early feasibility studies. We evaluate payload compatibility, loading sequence, gastrointestinal-stability approach, targeting modification route, and delivery performance in the agreed intestinal cell models. | Inquiry |
Tell us your payload, target intestinal segment, and delivery route, and BOC Sciences will propose an intestine-targeting strategy that fits your project.
Projects can begin with an existing LNP formulation, a candidate targeting ligand, or only a delivery objective. We organize the work into four practical stages and refine the plan as stability, transport, and biological evidence becomes available.

We review the payload class, target segment — duodenum, jejunum, ileum, or colon — intended cell population (enterocytes, M cells, goblet-cell-associated models, intestinal macrophages), baseline formulation if available, and desired biological readouts. The administration route — oral, rectal/local, or systemic — is fixed at this stage because it determines the barrier profile the formulation must clear.

We propose candidate ionizable lipids, helper lipid and cholesterol balances, and PEG-lipid architectures, then select the targeting layer — transporter-substrate ligands, receptor-recognition ligands, or composition-driven intestinal preference. Ratios are optimized through structured LNP lipid ratio optimization services, and each design includes matched non-targeted control LNPs.

Candidates are prepared under controlled mixing conditions, including microfluidic LNP production services where compositional screening demands tight reproducibility, and compared for particle size, PDI, zeta potential, ligand density, and payload retention. Gastroprotective formats — enteric coatings or microencapsulation — are applied at this stage when the route requires them, and only candidates meeting agreed particle-attribute thresholds advance.

Selected candidates are exposed to sequential simulated gastric and intestinal fluids, then compared for mucus diffusion, epithelial uptake, and trans-epithelial transport with apparent permeability (Papp) readouts in polarized monolayers. Functional endpoints — reporter expression, gene knockdown, or editing outcomes — are measured in intestinal cell and organoid models. In vivo studies combine nanoparticle in vivo distribution analysis with segment-level intestinal quantification and hepatic or splenic off-target measurement. Findings are summarized as a comparative dataset with documented design tradeoffs and suggested next experiments.
An intestine-targeted LNP may be well characterized in buffer yet fail completely after administration — degraded in the lumen, trapped in mucus, taken up by the wrong cells, or cleared by the liver. We investigate formulation and biological factors together and use matched comparison studies to identify the step limiting performance.
Gastric acid (pH 1–3), bile salts, pancreatic lipases, and luminal nucleases can destabilize particles and strip payloads before they reach the epithelium. We expose every candidate to sequential simulated gastric and intestinal fluids and quantify payload retention at defined time points, then correct the limiting factor — ionizable lipid structure, cholesterol content, surface composition, or the absence of a gastroprotective format — instead of assuming that a stable-in-buffer particle is stable in vivo.
The mucus layer is a dense, negatively charged hydrogel that immobilizes many cationic or large particles, while mucoadhesive designs trade uptake for retention. We measure mucus diffusion and mucin binding for each surface design, then tune particle size, surface charge, and PEG-lipid density to position each formulation on the retention-versus-penetration spectrum that fits the target segment, verifying the effect in transwell transport rather than uptake-only assays.
Gastrointestinal fluid contains little apolipoprotein E, so the uptake pathway that drives conventional intravenous LNP transfection barely operates in the lumen, and polarized epithelium with tight junctions resists particle internalization. We add uptake mechanisms deliberately — transporter-substrate ligands, receptor-recognition single-domain antibodies, or fusogenic helper lipids — and compare intracellular localization with functional readouts, applying LNP endosomal escape evaluation to identify post-uptake limitations before reformulating.
Delivery can differ widely between intestinal segments, between inflamed and healthy tissue, and between luminal retention and systemic absorption into liver and spleen. We use labeled particles and compartment-aware readouts to map where the payload actually accumulates, then adjust coating dissolution behavior, ligand density, and composition to increase inflamed- or segment-specific enrichment relative to off-target organs rather than reporting total signal alone.
Tell us about your current lipid composition, dosage format, payload, and evaluation results. BOC Sciences can help investigate the limiting formulation parameters and establish a focused optimization plan.
Intestine-targeted LNPs open delivery opportunities for nucleic acids, proteins, and small molecules in inflammatory bowel disease, gastrointestinal oncology, mucosal immunity, and epithelial repair research. BOC Sciences supports customized LNP development for these applications, including payload selection, lipid and ligand engineering, gastroprotective format development, and functional delivery evaluation.
Tell us your intended application and development requirements. Drawing on our experience and relevant published research, BOC Sciences can help design, synthesize, formulate, and evaluate intestine-targeted LNPs tailored to your project.
We map every formulation decision to a specific gastrointestinal barrier — luminal degradation, mucus entrapment, epithelial uptake, or endosomal escape — so that optimization targets the step actually limiting delivery rather than the easiest variable to change.

Our workflows cover bile-acid transporter substrates, epithelial receptor-recognition antibodies and single-domain antibodies, M-cell-oriented ligands, and mucus-compatible surface designs, allowing the targeting layer to be matched to the intestinal segment and cell population rather than forced onto a fixed platform.
Beyond particle formulation, we develop enteric coatings, microencapsulation, and lyophilized powder formats, and verify each format in simulated gastric and intestinal media — connecting dosage-form decisions directly to LNP performance instead of treating them as separate workstreams.
Simulated-fluid stability, mucus diffusion, epithelial transport, organoid and cell-model functional readouts, and segment-level in vivo distribution are combined in one program, so that formulation changes can be interpreted against both barrier and tissue-level delivery data.
From lipid synthesis and ligand conjugation to gastroprotective formatting, characterization, and intestinal delivery evaluation, the full development chain is handled within one integrated plan, reducing the disconnect between targeting chemistry and real intestinal performance.
Maintaining LNP integrity during gastrointestinal transit requires consideration of gastric acidity, digestive enzymes, bile salts, and changing intestinal conditions. Formulation strategies include optimizing ionizable lipid structures, helper phospholipids, cholesterol content, and PEG-lipid composition to reduce particle disruption and premature payload leakage. Protective excipients or external enteric coatings can provide additional protection when oral delivery is intended. BOC Sciences supports gastrointestinal stability evaluation using simulated gastric and intestinal media, together with particle characterization and payload integrity analysis, helping identify formulations that retain their structural and functional properties before reaching the intended intestinal region.
Intestinal mucus can trap nanoparticles through electrostatic, hydrophobic, and steric interactions with mucin networks. To improve mucus penetration, LNP formulations can be optimized through particle size control, surface charge adjustment, PEG-lipid selection, and surface hydrophilicity modification. However, mucus penetration and mucus adhesion serve different purposes: highly adhesive particles may provide local retention but exhibit limited transport toward epithelial cells. BOC Sciences can compare surface compositions and evaluate particle transport and retention using appropriate mucus models, helping determine whether a formulation is better suited for mucosal penetration, local retention, or subsequent epithelial delivery.
Colon-selective LNP delivery can be explored by combining gastrointestinal protection with region-dependent release mechanisms. External enteric coatings may protect LNPs during gastric transit, while pH-responsive polymers or enzyme-sensitive matrices can be designed to promote release in selected intestinal regions. Microencapsulation provides another approach by incorporating preformed LNPs into protective polymeric structures. The coating or matrix must be evaluated separately from the encapsulated LNP to confirm that particle integrity is preserved after release. BOC Sciences supports formulation development, coating optimization, release characterization, and intestinal distribution evaluation for colon-oriented delivery research.
Yes. Intestinal macrophage targeting can be investigated through ligand-functionalized LNPs that recognize accessible receptors on selected macrophage populations. Carbohydrate-based ligands, including appropriately designed galactose-containing structures, can be explored according to receptor expression and recognition mechanisms. Peptides and other receptor-binding components may also be considered when suitable targets are identified. Successful targeting requires more than increased particle association; receptor accessibility, cellular internalization, intracellular payload release, and functional gene modulation should all be evaluated. BOC Sciences supports ligand synthesis, lipid-anchor conjugation, surface-density optimization, and macrophage-associated cellular delivery studies.
Intestinal LNP evaluation should combine physicochemical characterization, gastrointestinal stability testing, cellular studies, and tissue-level analysis. Particle size, PDI, zeta potential, morphology, encapsulation efficiency, and payload integrity establish the initial formulation profile. Simulated gastric and intestinal media can assess particle stability, while mucus models help investigate transport and retention. Intestinal epithelial and macrophage models can be used to examine cellular uptake and functional payload activity through reporter expression or target-gene modulation. For studies, tissue imaging, intestinal segment analysis, and organ distribution measurements help distinguish local accumulation from productive cellular delivery.